Business Wire Feed
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas more...
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ALOFT--Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACTION--BMS Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101
Insulet Announces Omnipod Discover Now Available in U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed more...
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression outcomes with BRIUMVI® (ublituximab-xiiy) compared with ocrelizumab more...
Doctors, Public Health Experts and Dental Leaders Call for Oral Health to Become Part of Everyday Health Care
GENEVA--(BUSINESS WIRE)--Doctors, public-health experts and dental leaders are calling for oral health to be treated as part of overall health. Their message is clear: healthier teeth and gums matter beyond the mouth, and effective daily more...
Fujifilm Launches Synapse Pathology v3.0, Advancing the Digital Pathology Experience With Expanded AI Capabilities
LEXINGTON, Mass.--(BUSINESS WIRE)--FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, today announced the launch of Synapse® Pathology v3.0. Featuring more than 50 new features and functions, Synapse Pathology v3.0 is more...
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome
GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with more...
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with more...
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, more...
Verda Healthcare, Inc. and AstranaCare Partners Form a Multi-State Partnership
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)-- #healthinsurance--Verda Healthcare, Inc. is proud to announce a new partnership with AstranaCare Partners of Arizona and AstranaCare Partners of Texas. AstranaCare, through a large network of Independent Physician Associations (IPAs), enables more...
AHF Debuts ‘Wellness on Wheels’ – New EV Mobile Clinic During ‘Pride on Paradise’
LAS VEGAS--(BUSINESS WIRE)-- #AHFcares--AIDS Healthcare Foundation (AHF), the world’s largest nonprofit public health organization, is debuting a new environmentally friendly, electric mobile (EV) unit to increase access to free testing, prevention and treatment services for more...
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company more...
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to more...
Reinsurance Group of America Announces Third Quarter Earnings Release Date, Webcast
ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE:RGA) plans to release third quarter earnings on Thursday, November 5, at approximately 4:15 p.m. Eastern Time. The release will be issued via newswire and will also be more...
Zoetis Declares Fourth Quarter 2026 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, more...
Concentra to Announce Third Quarter 2026 Results on Thursday, November 5, 2026
DALLAS--(BUSINESS WIRE)--Concentra® Group Holdings Parent, Inc. (“Concentra”) (NYSE: CON) will release the financial results for its third quarter ended September 30, 2026, on Thursday, November 5, 2026, after the market closes. Concentra will host a more...
FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab more...
Ascensia Announces Strategic Partnership with Sava for Innovative Microsensor Technology
BASEL, Switzerland--(BUSINESS WIRE)-- #Diabetes--Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TYO 6523), today announced a strategic partnership with venture-backed health technology startup Sava Technologies to support the introduction more...
Humana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), a leading consumer healthcare company focused on helping people achieve their best health, today announced improved Star Ratings for 2027, highlighted by 95% of its Medicare Advantage members being more...
Stuart Therapeutics Expands Pipeline with Corneal Wound Healing Program
STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics Inc., a late-stage biopharmaceutical company developing a new class of therapeutics designed to treat eye diseases by repairing helical collagen, today announced it has submitted an investigational new drug application amendment more...
Secretome Therapeutics to Present Phase 1 Clinical Data Evaluating STM-01 in Heart Failure with Preserved Ejection Fraction at HFSA Annual Scientific Meeting
PLANO, Texas--(BUSINESS WIRE)-- #CardiovascularResearch--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced that clinical data from its Phase 1 study evaluating STM-01 in patients with heart more...
Blueberry Medical (“Blueberry”) Security Incident
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--On August 10, an unauthorized actor exploited a critical vulnerability in the Metabase platform to obtain administrator access to Blueberry’s Metabase environment. The activity was associated with broader exploitation of the Metabase more...
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food more...